Fig. 5

Intra-tumor injection of 122-Exo sensitizes HCC cells to sorafenib in vivo. a, b Tumor volume a and weight b measurement of HepG2 xenograft tumors at 35 days post-implantation (28 days after exosome administration combined with sorafenib treatment). c Imaging of mice at 35 days post-implantation. d, e Real-time PCR (d) and Western blot (e) analyses of miR-122-targeted gene expression in tumor samples at 35 days post-implantation. f Western blot analysis of apoptosis-related gene expression in the above tumor samples. Data are presented as means ± SE. (*p < 0.05, n = 5). Exo naïve AMSC-derived exosomes, 122-Exo AMSC-122-derived exosomes, 67-Exo AMSC-67-derived exosomes